Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.

Phase 4CompletedNCT00169546

GlaxoSmithKline64 enrolled

Overview

Comparison of two asthma treatments by lung function measures.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Asthma

Interventions

Salmeterol/fluticasone propionateDRUG

Fluticasone propionateDRUG

Eligibility

Sex: ALLMin age: 4 YearsMax age: 11 Years

Medical Language ↔ Plain English

Inclusion criteria: * Currently receiving 200-800mcg/day beclomethasone dipropionate. * sRAW value of 1.3 kPa's. Exclusion Criteria: * 3 or more courses of oral steroids in last 12 months.

Locations (2)

GSK Investigational Site

Wellington, New Zealand

GSK Investigational Site

Manchester, Lancashire, United Kingdom

Outcomes

Primary Outcomes

sRAW (k.Pa.s) measured before the study medication dose at the end of treatment (week 6)

Secondary Outcomes

sRAW measured pre-dose at Week 3. sRAW measured 48 hours after last study medication dose. % symptom-free days over Weeks 1-6. % symptom-free nights over Weeks 1-6. Type and frequency of adverse events.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.